查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1516931

治療藥監測的全球市場的評估:各產品，各技術，各類藥物，各終端用戶，各地區，機會，預測，2017年～2031年

Therapeutic Drug Monitoring Market Assessment, By Product, By Technology, By Drug Class, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期間，全球治療藥物監測市場規模將以9.56%的複合年增長率擴大，從2023年的17.7億美元增長到2031年的36.7億美元。醫療保健產業的擴張、對個人化用藥方案的需求不斷增加以及慢性病盛行率的增加推動了市場的成長。

治療藥物監測旨在幫助優化藥物療效、評估毒性並監測治療方案的依從性。美國癌症協會估計，到2024年，美國將新增2,001,140例癌症病例，611,720例相關死亡病例。

此外，各公司增加投資以擴大其智慧財產權組合正在擴大全球治療藥物監測市場規模。 2023 年 10 月，ProciseDx Inc. 宣布從 W. Health LP 購買了兩項美國專利。美國專利號11,085,931和美國專利號11,119,096這兩項專利與公司現有的智慧財產權結合，預計將擴大其在生物製劑治療藥物監測領域的足跡。生物製劑監測可透過提供個人化的生物製劑劑量，幫助醫療保健專業人員優化為發炎性腸道疾病 (IBD) 患者提供的照護。這項投資預計將使該公司能夠擴大其產品組合，並為更廣泛的客戶提供監控解決方案。

本報告提供全球治療藥監測市場相關調查，提供市場概要，以及各產品，各技術，各類藥物，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 摘要整理

第4章 全球治療藥監測市場預測，2017年～2031年

  • 市場規模與預測
  • 各產品
  • 各技術
  • 各類藥物
  • 各終端用戶
  • 各地區
  • 各企業市場佔有率(%)、2023年

第5章 全球治療藥監測市場預測，各地區(2017年～2031年)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 市場製圖，2023年

第7章 宏觀環境和產業結構

  • 供給需求分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第8章 市場動態

第9章 法規結構和革新

第10章 主要加入企業的形勢

第11章 價格分析

第12章 案例研究

第13章 主要加入企業預測

  • Abbott Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens AG
  • bioMerieux SA
  • Chromsystems Instruments & Chemicals GmbH
  • Randox Laboratories
  • Exagen Inc.

第14章 策略性建議

第15章 諮詢方式和免責聲明

Product Code: MX11623

Global therapeutic drug monitoring market is projected to witness a CAGR of 9.56% during the forecast period 2024-2031F, growing from USD 1.77 billion in 2023 to USD 3.67 billion in 2031F. The market's growth is augmented by the expansion of the healthcare sector, increasing requirement for personalized medication regime, and growing prevalence of chronic diseases.

The growing prevalence of various chronic diseases, such as cancer, across the globe is one of the major factors supporting the market's expansion as therapeutic drug monitoring helps in optimizing drug efficacy, assessing toxicity, and monitoring compliance with treatment regimen. According to the estimates of the American Cancer Society, 2,001,140 new cases of cancer and 611,720 related deaths are expected to occur in the United States in 2024.

Additionally, increasing investments by various companies towards the expansion of their intellectual property portfolio is bolstering the global therapeutic drug monitoring market size. In October 2023, ProciseDx Inc. announced that they had purchased two US patents from W. Health LP. The two patents, US Patent No. 11,085,931 and US Patent No. 11,119,096 coupled with the existing intellectual property of the company, expected to allow them in expanding their footprint in the therapeutic drug monitoring of biological drugs sector. The monitoring of biologics aids healthcare professionals in optimizing the care provided to patients suffering from inflammatory bowel disease (IBD) by providing personalized dosing of biologics. The investment is expected to aid the company in expanding their portfolio and offer monitoring solutions to a wider range of customers.

Meanwhile, novel products launched by various companies is one of the major global therapeutic drug monitoring market trends. In December 2023, lifespin GmbH launched their therapeutic drug monitoring software that will aid the laboratories to use algorithms for receiving antibiotic measurements of the patients. The company's product utilizes nuclear magnetic resonance (NMR) for testing antibiotics that are commonly used, such as Ceftriaxon, Cefuroxim, and Ceftazidim. The test rollout will happen with the help of the company's cloud system and the laboratories that will be in possession of the necessary hardware will be able to deploy the company's algorithm.

Increasing Organ Transplantation Boosts Market Demand

The rising requirement for organ transplantation due to the increasing prevalence of different chronic conditions such as cystic fibrosis, cancer, and acute and chronic hepatitis, among others is bolstering the global therapeutic drug monitoring market demand. According to the estimates of the Organ Procurement and Transplantation Network (OPTN), approximately 46,632 organ transplants were performed in 2023 from both deceased and living donors, representing an 8.7% increase from 2022 and 12.7% increase from 2021. The increase is propelling the global therapeutic drug monitoring market demand as various immunosuppressive medications are provided to the patient at different times to prevent the rejection of the transplanted organ by the recipient's body. To ensure that these medications are provided to the patient in a balance, therapeutic drug monitoring is deployed. One of the most common immunosuppressive agents, Tacrolimus is administered in both outpatient and inpatient settings in cases of solid organ transplant as a key immunosuppressive agent. Such agents require monitoring as it is essential to ensure that the serum levels of the patient remain stable over the course of treatment.

Increasing Investments Support Market Expansion

The growth of the market is supported by the rise in investments towards therapeutic drug monitoring platforms. In September 2023, Ghent University and Imec spin-offs, Axithra secured USD 10.7 million (EUR 10 million) in seed funding for developing a therapeutic drug monitoring platform that is able to measure the drug concentration in blood in an accurate and time efficient manner. Initially, Axithra is expected to deploy their technology for measuring beta-lactam antibiotic concentration in the blood of the patients. The class of antibiotics is administered to millions of patients every year that are in intensive care for prevent and treat bacterial infections. The therapeutic drug monitoring platform offered by Axithra will allow for tailored treatments for individual patients. The technology draws company's expertise in photonic wafer processing, in the field of silicon nitride in particular. The prototype is expected to be released in 2025. Such investments are expected to provide lucrative growth opportunities for the market as they allow the development of advanced technologies.

North America Holds a Significant Market Share

The growth of the market in North America is propelled by the presence of a well-established healthcare sector, expansion of geriatric population, increasing provision of approvals from different regulatory bodies in the region, and rising prevalence of infectious and chronic diseases. In May 2024, Saladax Biomedical, Inc., a leading biotechnology research company known for marketing, manufacturing, and developing assays responsible for providing rapid therapeutic drug levels for medicines, received approval from Health Canada for 5-Fluorouracil (5-FU) therapeutic drug monitoring (TDM) test. The 5-FU TDM test, known as My5-FU Assay aims to ensure accurate drug dosage to reduce toxicity and improve efficacy, thus optimizing patient care. The traditional dosing methods for 5-FU, that are body surface area (BSA) based are not known to account for individual patient difference. Saladax's assay allows healthcare professionals to adjust and measure 5-FU levels during a chemotherapy cycle, with the help of a single blood sample. Such approvals are expected to provide lucrative growth opportunities to the market in North America in the forecast period.

Antiepileptic Drugs Account for a Significant Market Share

The increase in the number of cases of epilepsy across the globe is propelling the segment's expansion by bolstering the requirement for antiepileptic drugs. According to the estimates of the World Health Organization (WHO), approximately 50 million individuals across the globe suffer from epilepsy. The optimal implementation of therapeutic drug monitoring can aid in enhancing clinical care for antiepileptic drugs with complex pharmacokinetics and complement clinical decision making in the management of the condition.

Meanwhile, immunosuppressant drugs are expected to witness significant growth in the coming years due to the rising requirement of organ transplant and increase in the number of cases of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. According to the estimates of WHO, in 2023, over 1.8 million individuals suffered from multiple sclerosis, globally.

Future Market Scenario (2024 - 2031F)

Therapeutic drug monitoring technologies are expected to aid in optimizing personalized dosing and determining the clinical efficacy of drugs in patients, thus enabling precision medicine strategies. The rapid evolutions in nanomaterials coupled with preparation and manufacturing of optical and electrochemical biosensors along with their integration in wearables is expected to provide several advantages in therapeutic drug monitoring. Therapeutic drug monitoring analyses are expected to shed light on determining the correct method of prescribing drugs to improve clinical outcomes. Due to costly nature of therapeutic drug monitoring, the sector is expected to benefit through investments from therapeutic developers and organizations. The integration of therapeutic drug monitoring in precision medicine has the potential to improve patient outcomes. The requirement for therapeutic drug monitoring is expected to propel due to the rising prevalence of autoimmune diseases, epilepsy, cardiovascular diseases, fungal infections, bacterial infections, and psychiatric diseases.

Key Players Landscape and Outlook

Strategic collaborations by key market players are expected to bolster the global therapeutic drug monitoring market growth. In July 2021, Thermo Fisher Scientific Inc. announced partnership with Mindray to develop reliable biochemistry solutions for testing drug abuse. The two chemistry analyzers will be available for drug screening in court and clinical laboratories in Canada and the United States. With its partnership, the companies aim to address the requirements of their customers in criminal justice, hospitals, and commercial settings. To provide access to drug testing, both companies have entered in an agreement to offer the Health Canada-approved and FDA-cleared BA-800M (800 tests/hour) and BS-480 (400 tests/hour) analyzers to toxicology laboratories. Such partnerships are expected to aid the market players in strengthening their position and expanding their customer base.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Therapeutic Drug Monitoring Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Equipment
    • 4.2.2. Consumables
  • 4.3. By Technology
    • 4.3.1. Immunoassays
    • 4.3.2. Chromatography-Mass Spectrometry
    • 4.3.3. Electrophoresis
    • 4.3.4. Proteomic Technology
    • 4.3.5. Others
  • 4.4. By Drug Class
    • 4.4.1. Antiepileptic Drugs
    • 4.4.2. Antiarrhythmic Drugs
    • 4.4.3. Immunosuppressant Drugs
    • 4.4.4. Antibiotic Drugs
    • 4.4.5. Psychoactive Drugs
    • 4.4.6. Bronchodilator Drugs
    • 4.4.7. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Diagnostic Laboratories
    • 4.5.3. Research and Academic Institutes
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. South America
    • 4.6.3. Europe
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Therapeutic Drug Monitoring Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Equipment
      • 5.1.2.2. Consumables
    • 5.1.3. By Technology
      • 5.1.3.1. Immunoassays
      • 5.1.3.2. Chromatography-Mass Spectrometry
      • 5.1.3.3. Electrophoresis
      • 5.1.3.4. Proteomic Technology
      • 5.1.3.5. Others
    • 5.1.4. By Drug Class
      • 5.1.4.1. Antiepileptic Drugs
      • 5.1.4.2. Antiarrhythmic Drugs
      • 5.1.4.3. Immunosuppressant Drugs
      • 5.1.4.4. Antibiotic Drugs
      • 5.1.4.5. Psychoactive Drugs
      • 5.1.4.6. Bronchodilator Drugs
      • 5.1.4.7. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Diagnostic Laboratories
      • 5.1.5.3. Research and Academic Institutes
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
        • 5.1.6.1.1. By Value
        • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Product
        • 5.1.6.2.1. Equipment
        • 5.1.6.2.2. Consumables
      • 5.1.6.3. By Technology
        • 5.1.6.3.1. Immunoassays
        • 5.1.6.3.2. Chromatography-Mass Spectrometry
        • 5.1.6.3.3. Electrophoresis
        • 5.1.6.3.4. Proteomic Technology
        • 5.1.6.3.5. Others
      • 5.1.6.4. By Drug Class
        • 5.1.6.4.1. Antiepileptic Drugs
        • 5.1.6.4.2. Antiarrhythmic Drugs
        • 5.1.6.4.3. Immunosuppressant Drugs
        • 5.1.6.4.4. Antibiotic Drugs
        • 5.1.6.4.5. Psychoactive Drugs
        • 5.1.6.4.6. Bronchodilator Drugs
        • 5.1.6.4.7. Others
      • 5.1.6.5. By End-user
        • 5.1.6.5.1. Hospitals
        • 5.1.6.5.2. Diagnostic Laboratories
        • 5.1.6.5.3. Research and Academic Institutes
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Technology
  • 6.3. By Drug Class
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Abbott Healthcare Private Limited
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Thermo Fisher Scientific Inc.
  • 13.3. Bio-Rad Laboratories, Inc.
  • 13.4. F. Hoffmann-La Roche Ltd.
  • 13.5. Danaher Corporation
  • 13.6. Siemens AG
  • 13.7. bioMerieux SA
  • 13.8. Chromsystems Instruments & Chemicals GmbH
  • 13.9. Randox Laboratories
  • 13.10. Exagen Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 6. Global Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Therapeutic Drug Monitoring Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 11. North America Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 12. North America Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 13. North America Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Therapeutic Drug Monitoring Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 18. United States Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 19. United States Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 20. United States Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 24. Canada Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 25. Canada Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Canada Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 30. Mexico Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 31. Mexico Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 32. Mexico Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 36. Europe Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 37. Europe Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 38. Europe Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Therapeutic Drug Monitoring Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 43. Germany Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 44. Germany Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 45. Germany Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 49. France Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 50. France Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 51. France Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 55. Italy Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 56. Italy Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. Italy Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 61. United Kingdom Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 62. United Kingdom Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 63. United Kingdom Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 67. Russia Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 68. Russia Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 69. Russia Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 73. Netherlands Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 74. Netherlands Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 75. Netherlands Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 79. Spain Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 80. Spain Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 81. Spain Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 85. Turkey Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 86. Turkey Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 87. Turkey Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 91. Poland Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 92. Poland Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Poland Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 97. South America Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 98. South America Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. South America Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Therapeutic Drug Monitoring Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 104. Brazil Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 105. Brazil Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 106. Brazil Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 110. Argentina Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 111. Argentina Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 112. Argentina Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 116. Asia-Pacific Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 117. Asia-Pacific Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 118. Asia-Pacific Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Therapeutic Drug Monitoring Market Share (%), By Country, 2017-2031F
  • Figure 120. India Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 123. India Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 124. India Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 125. India Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 129. China Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 130. China Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 131. China Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 135. Japan Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 136. Japan Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 137. Japan Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 141. Australia Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 142. Australia Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 143. Australia Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 147. Vietnam Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 148. Vietnam Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 149. Vietnam Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 153. South Korea Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 154. South Korea Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 155. South Korea Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 159. Indonesia Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 160. Indonesia Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 161. Indonesia Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 165. Philippines Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 166. Philippines Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 167. Philippines Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 171. Middle East & Africa Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 172. Middle East & Africa Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 173. Middle East & Africa Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Therapeutic Drug Monitoring Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 178. Saudi Arabia Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 179. Saudi Arabia Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 180. Saudi Arabia Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 184. UAE Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 185. UAE Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 186. UAE Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Therapeutic Drug Monitoring Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Therapeutic Drug Monitoring Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Therapeutic Drug Monitoring Market Share (%), By Product, 2017-2031F
  • Figure 190. South Africa Therapeutic Drug Monitoring Market Share (%), By Technology, 2017-2031F
  • Figure 191. South Africa Therapeutic Drug Monitoring Market Share (%), By Drug Class, 2017-2031F
  • Figure 192. South Africa Therapeutic Drug Monitoring Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023